FGFR2 and neoplasm: Notably, when treated with a panel of FGFR inhibitors, NIH-3T3 and Ba/F3 model cell lines expressing FGFR2 W290C, and S320C mutants or FGFR3 R248C and S249C mutants, showed a significant reduction in cell survival, a reduction in cell transformation in anchorage-independent conditions and a reduction in tumour volume in xenograft mouse models [28].